CoChat

AV-65, a novel Wnt/β-catenin signal inhibitor, successfully suppresses progression of multiple myeloma in a mouse model

Open access
Yao, H, Ashihara, E, Strovel, J W, Nakagawa, Y, Kuroda, J, Nagao, R, Tanaka, R, Yokota, A, Takeuchi, M, Hayashi, Y, Shimazaki, C, Taniwaki, M, Strand, K, Padia, J, Hirai, H, Kimura, S, Maekawa, T · 2011 · Blood Cancer Journal
Cited by 48

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Multiple myeloma (MM) is a malignant neoplasm of plasma cells. Although new molecular targeting agents against MM have been developed based on the better understanding of the underlying pathogenesis, MM still remains an incurable disease. We previously demonstrated that β-catenin, a downstream effector in the Wnt pathway, is a potential target in MM using RNA interference in an in vivo experimental mouse model. In this study, we have screened a library of more than 100 000 small-molecule chemical compounds for novel Wnt/β-catenin signaling inhibitors using a high-throughput transcriptional screening technology. We identified AV-65, which diminished β-catenin protein levels and T-cell factor transcriptional activity. AV-65 then decreased c-myc, cyclin D1 and survivin expression, resulting in the inhibition of MM cell proliferation through the apoptotic pathway. AV-65 treatment prolonged the survival of MM-bearing mice. These findings indicate that this compound represents a novel and attractive therapeutic agent against MM. This study also illustrates the potential of high-throughput transcriptional screening to identify candidates for anticancer drug discovery.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/bcj.2011.41

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 48

Metadata

Authors
Yao, H., Ashihara, E., Strovel, J. W., Nakagawa, Y., Kuroda, J., Nagao, R., Tanaka, R., Yokota, A., Takeuchi, M., Hayashi, Y., Shimazaki, C., Taniwaki, M., Strand, K., Padia, J., Hirai, H., Kimura, S., & Maekawa, T.
Venue
Blood Cancer Journal
Published
2011-11-04
Volume
1
Issue
11
Pages
e43-e43
ISSN
2044-5385 (ISSN-L)
OpenAlex
W2167780668
Cited by
48
References
2
FWCI
2.45
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: AV-65, a novel Wnt/β-catenin signal inhibitor, successfully suppresses progression of multiple myeloma in a mouse model. https://app.cochat.ai/papers/10.1038/bcj.2011.41
The paper
Yao, H., Ashihara, E., Strovel, J. W., Nakagawa, Y., Kuroda, J., Nagao, R., Tanaka, R., Yokota, A., Takeuchi, M., Hayashi, Y., Shimazaki, C., Taniwaki, M., Strand, K., Padia, J., Hirai, H., Kimura, S., & Maekawa, T. (2011). AV-65, a novel Wnt/β-catenin signal inhibitor, successfully suppresses progression of multiple myeloma in a mouse model. Blood Cancer Journal. https://doi.org/10.1038/bcj.2011.41

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.